FIELD: medicine.
SUBSTANCE: invention represents a liquid dosage form of a hopantenic acid calcium salt possessing nootropic activity, containing an effective amount of the hopantenic acid calcium salt and additive agents. It represents drops, and as additive agents, it contains benzoic acid, sodium saccharinate, an orange flavour, hydrochloric 1M, Trilon B and water.
EFFECT: higher active substance content by improving its organoleptic properties and reducing a viscosity of the liquid dosage form by reducing the content of viscosity-enhancing agents and increasing the water content.
2 cl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| LIQUID DOSAGE FORM FOR ORAL ADMINISTRATION, HAVING NOOTROPIC ACTIVITY | 2018 |
|
RU2703293C1 |
| NOOTROPIC PREPARATION | 2001 |
|
RU2177783C1 |
| COMPOSITION HAVING ACTION ON CENTRAL NERVOUS SYSTEM AND USING IT | 2013 |
|
RU2546300C1 |
| METHOD OF PRODUCING 4-AMINOBUTYRIC ACID DERIVATIVES OR CALCIUM OR LYSINE SALT THEREOF | 0 |
|
SU1340582A3 |
| PHARMACEUTICAL COMPOSITION CONTAINING MEMANTINE AND MELATONIN COMBINATION | 2016 |
|
RU2623865C1 |
| PREPARATION FLAVOSUCCINE FOR TREATING AND PREVENTING RENAL AND URINARY DISEASES | 2010 |
|
RU2456011C1 |
| AGENT HAVING NOOTROPIC EFFECT ON BODY | 2017 |
|
RU2694233C2 |
| PHARMACEUTICAL COMPOSITION POSSESSING GABA ACTIVITY | 2012 |
|
RU2496496C1 |
| LIQUID PHARMACEUTICAL COMPOSITION OXYETHYLAMMONIUM METHYLPHENOXYACETATE | 2021 |
|
RU2783660C2 |
| FURAZIDIN COMPOSITION IN THE FORM OF A SUSPENSION AND A METHOD FOR ITS PREPARATION | 2018 |
|
RU2770041C2 |
